2 results
Approved WMOWill not start
The purpose of this clinical investigation is to evaluate the effectiveness of modified Sensor designs on the longevity (up to a maximum of 90 days) of the Senseonics Continuous Glucose Monitoring (CGM) System. The investigation will also evaluate…
Approved WMOCompleted
PART B (FL phase IIb *PARADIGME*):Primary objective:Randomised section of Part B- To evaluate the efficacy of the *40/15* dose regimen (40 mg lilotomab / 15 MBq/kg Betalutin) compared with *100/20* dose regimen (100 mg/m2 lilotomab/ 20 MBq/kg…